Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
15.9M
-
Shares change
-
+749K
-
Total reported value, excl. options
-
$154M
-
Value change
-
+$4.66M
-
Number of buys
-
40
-
Number of sells
-
-31
-
Price
-
$9.73
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q4 2017
87 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q4 2017.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.9M shares
of 28M outstanding shares and own 56.71% of the company stock.
Largest 10 shareholders include FMR LLC (3.94M shares), Flagship Pioneering Inc. (3.2M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.27M shares), WELLINGTON MANAGEMENT GROUP LLP (997K shares), ARK Investment Management LLC (835K shares), Redmile Group, LLC (637K shares), Vanguard Group Inc (582K shares), BlackRock Inc. (575K shares), BAKER BROS. ADVISORS LP (575K shares), and Aisling Capital LLC (509K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.